New Zealand Industry body objects government restriction on Levomefolate

Levomefolate is a biologically active form of folate. The Medicines Classification Committee (MCC) recently put out a proposal to schedule products containing more than 500 mcg levomefolate per day as a pharmacy-only product. Industry body NHPNZ has raised concerns stating that International regulators have determined that levomefolate is safe at a daily dose of 1 mg per day and Restricting it will limit export opportunities .However, The MCC argues that the scheduling of levomefolate would not necessarily indicate that all products containing the substance are medicines, citing the examples of folic acid and potassium.